Imaging, pathology review, and the multidisciplinary care team
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
Most cutaneous squamous cell carcinomas (SCCs) are diagnosed with a single skin biopsy and treated with one office procedure. No scans, no specialists, no waiting. When an SCC is advanced — large or deep, growing along nerves, recurring after treatment, or spreading to lymph nodes — the evaluation becomes more involved.
The point of this workup is to answer a few questions before anyone picks a treatment: exactly how far has the tumor grown, is there any sign it has traveled, how aggressive does it look under the microscope, and which combination of specialists should be involved. The answers determine whether the plan is surgery, surgery plus radiation, radiation alone, systemic medication, or a clinical trial.
This guide walks through each part of that evaluation — pathology re-review, imaging, staging, and the tumor board — so you know what to expect and why each step matters.
A small, new SCC on the forearm can be measured with a ruler and seen in its entirety by the naked eye. An advanced tumor often cannot. It may extend under normal-looking skin, track along a nerve toward the skull base, invade the parotid gland, or seed a lymph node in the neck. How wide a margin to take, whether radiation is needed, whether to start medication first — all of it depends on knowing the true extent of the disease.
A thorough workup also prevents surprises. Discovering mid-surgery that a tumor reaches the eye socket or wraps a major nerve is far worse than knowing beforehand and planning for it. The steps below are designed to map the tumor completely, check whether it has spread, and bring the right specialists in from the start.
The tissue diagnosis drives much of what follows, so for advanced disease a dermatopathologist at the treating center usually re-reads the original biopsy slides. If the first sample was shallow or fragmented, a deeper or repeat biopsy may be done so the full growth pattern can be seen. A complete report for a high-risk SCC should specify:
These are the same features that push a tumor into the "high-risk" category on the staging systems described below — see what makes an SCC "high-risk".
Imaging is not routine for SCC. It is added when the exam or pathology raises specific concerns — a tumor whose edges cannot be judged by looking and feeling, suspected involvement of bone or deep tissue, symptoms of nerve involvement, recurrent disease, a tumor near the eye, ear, or parotid, or an abnormal lymph node. In studies of high-stage tumors, cross-sectional imaging changed management in roughly a quarter to a third of cases.
Scans have limits: very small nerve involvement or thin sheets of tumor can be invisible on imaging, so a normal scan does not always mean the tumor is small. Doctors combine imaging with the exam and pathology rather than relying on any one piece. For how nodes are assessed and when a sentinel node biopsy is offered, see when SCC spreads to lymph nodes.
Once the pathology and imaging are in, the tumor is staged. Two systems are used for cutaneous SCC of the head and neck, and many centers report both:
The American Joint Committee on Cancer system, revised in 2017, assigns a T category from tumor size and features such as deep invasion, bone involvement, and perineural invasion, plus N and M categories for nodes and distant spread. It is the system most cancer registries and trials use.
The BWH system counts four risk factors — tumor 2 cm or larger, poor differentiation, perineural invasion of a nerve 0.1 mm or wider, and invasion beyond the fat — and sorts tumors into T1, T2a, T2b, or T3. In published comparisons it has concentrated the poor outcomes into a smaller, better-defined high-risk group (T2b/T3) than AJCC8, which helps target imaging and closer follow-up.
Staging is not just paperwork: a T2b or T3 tumor is the kind that a team watches closely, images, and often treats with surgery plus radiation. More detail is on the SCC hub's staging and grading page.
Advanced SCC is managed by a group rather than a single doctor. You may not meet everyone on this list, but each has a defined role:
Often makes the diagnosis and coordinates the workup, and performs margin-controlled surgery when the tumor is still resectable.
Handles large resections involving cartilage, bone, the parotid gland, or the orbit, and performs lymph node surgery (neck dissection or sentinel node biopsy) when needed.
Delivers radiation as a primary treatment for inoperable tumors or after surgery when the recurrence risk is high — for example with perineural invasion, positive margins, or nodal disease.
Prescribes and monitors systemic therapy — a PD-1 inhibitor such as cemiplimab or pembrolizumab — when surgery and radiation are not enough, and manages side effects.
Interpret the tissue and the scans, and re-review outside material so everyone is working from the same information.
Plans how a large defect will be closed or rebuilt, which sometimes shapes the surgical approach itself.
Involved when someone takes anti-rejection or other immune-suppressing drugs, because those medications drive more aggressive SCC and complicate the decision to use immunotherapy. See advanced SCC in transplant recipients.
Support side-effect management, transportation and cost concerns, nutrition before radiation to the mouth or throat, and dental care.
Many centers bring these specialists together at a tumor board — a meeting where a complex case is presented and the group agrees on a recommendation. Your case can be reviewed there without you attending; you then hear the combined plan from your primary doctor.
The workup is also where the team looks at the whole person, not just the tumor:
Bringing these up early means fewer detours later, and it keeps every path — including shrinking the tumor before surgery — on the table before a plan is locked in.
The evaluation for advanced SCC is more thorough than for an ordinary skin cancer because the anatomy and the stakes are more complex. A close re-read of the pathology, targeted imaging when it is warranted, formal staging, and input from several specialties together produce a treatment plan built on a complete picture of the tumor.
If any part of your workup feels rushed or unclear, it is reasonable to ask for the tumor to be fully mapped and staged before a treatment decision is made — and to bring a written list of questions to each visit.
Disclaimer: This article is for educational purposes only and not a substitute for professional medical advice. Always consult a qualified dermatologist or oncologist about your personal diagnosis and treatment plan.
Chat with our AI guide for information about how advanced squamous cell carcinoma is evaluated
Chat with the Navigator